Stock Market News
Jefferies ups target price on Indivior ahead of Sublocade launch
Encouraged by Indivior's update on the launch of its Sublocade monthly opioid addiction treatment, Jefferies showed its confidence in the drug maker with an improved target price and a reiterated 'buy' rating.
While reported sales were down 8.4% across the US in the first quarter, Jefferies analysts noted that a one-off de-stocking effect was responsible for around 3-4% of the weakness, leading them to forecast a slight increase to net price erosion from less favourable payer mix.
The analysts expect sales of Sublocade, a once-monthly injectable buprenorphine formulation for the treatment of 'moderate-to-severe' opioid addiction, to be minimal in the first half of the year, however, the firm indicated that its initial launch had been encouraging, with positive feedback from both patients and doctors.
"Demand appears to be strong, such that the company's go-to-market Insupport hub has experienced some logistical challenges given the volume of patients, but we expect increased investment and resources here should rectify those at this early stage," the Tuesday report from Jefferies read. "We are encouraged by the initial launch and maintain our bullish stance."
"Despite a recent strong share price move, we continue to believe the market is overly discounting Sublocade and there is still compelling upside to the current share price, in our view."
Jefferies upped Indivior's price target to 630p, from 610p, and reiterated its 'buy' stance on the stock.
While reported sales were down 8.4% across the US in the first quarter, Jefferies analysts noted that a one-off de-stocking effect was responsible for around 3-4% of the weakness, leading them to forecast a slight increase to net price erosion from less favourable payer mix.
The analysts expect sales of Sublocade, a once-monthly injectable buprenorphine formulation for the treatment of 'moderate-to-severe' opioid addiction, to be minimal in the first half of the year, however, the firm indicated that its initial launch had been encouraging, with positive feedback from both patients and doctors.
"Demand appears to be strong, such that the company's go-to-market Insupport hub has experienced some logistical challenges given the volume of patients, but we expect increased investment and resources here should rectify those at this early stage," the Tuesday report from Jefferies read. "We are encouraged by the initial launch and maintain our bullish stance."
"Despite a recent strong share price move, we continue to believe the market is overly discounting Sublocade and there is still compelling upside to the current share price, in our view."
Jefferies upped Indivior's price target to 630p, from 610p, and reiterated its 'buy' stance on the stock.
Related share prices |
---|
Indivior (INDV) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price